Jingze Biotech

Jingze Biotech is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focused on the development and commercialization of high-quality biosimilars and innovative biologics. The company targets therapeutic areas with high clinical demand, particularly ophthalmology, oncology, and metabolic diseases. Its advanced pipeline includes biosimilars for major drugs such as ranibizumab, aflibercept, and denosumab, with several candidates in Phase 3 clinical trials or at the NDA submission stage. Jingze Biotech operates integrated R&D and large-scale GMP manufacturing facilities to ensure the production of cost-effective biological therapies. The company aims to improve patient access to critical treatments through its robust technical expertise in protein engineering and process development.